Contrasting effects of conjugated estrogens and tamoxifen on dilator responses of atherosclerotic epicardial coronary arteries in nonhuman primates

Circulation

Volumn 96, Issue 6, 1997, Pages 1970-1975

  Williams, J Koudy ^a   Honoré, Erika K ^a,b   Adams, Michael R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Arteries; Atherosclerosis; Hormones; Tamoxifen; Vasculature

Indexed keywords

ACETYLCHOLINE; CONJUGATED ESTROGEN; ESTROGEN RECEPTOR; GLYCERYL TRINITRATE; LIPOPROTEIN; TAMOXIFEN; TAMOXIFEN CITRATE;

ANGIOCARDIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; EPICARDIUM; FEMALE; INTRACORONARY INFUSION; LIPOPROTEIN BLOOD LEVEL; MACACA; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARIECTOMY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; VASODILATATION;

EID: 0030801297     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.6.1970     Document Type: Article

References (46)

1. Early Breast Cancer Triallists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 1992;339:1-15.
2. Bonadonna G, Valagussa P, Brambilla C, Moliterni A, Zambitti M, Ferrari LS. Adjuvant and neoadjuvant treatment of breast cancers with chemotherapy and endocrine therapy. Semin Oncol. 1991;18: 515-524.
3. Powles TJ. The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet. 1992;340:1145-1147.
4. Fugh-Berman A, Epstein S. Tamoxifen: disease prevention or disease substitution? Lancet. 1992;340:1143-1145.
5. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial: the Scottish Breast Cancer Committee. Br Med J. 1993;303:435-437.
6. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861-1867.
7. Rossner S, Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis. 1984; 53:339-346.
8. Bruning PF, Bonfrer JMG, Hart AAM, de Jong-Bakker M, Linders D, van Loon J, Nooyen WJ. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer. 1988;58:497-499.
9. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, DeMets DL. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst. 1990;82:1327-1332.
10. Bagdade JD, Wolter J, Subbaiah PV, Ryan W. Effects of tamoxifen treatment on plasma lipids and lipoprotein composition. J Clin Endocrinol Metab. 1990;70:1132-1135.
11. Ingram D. Tamoxifen use, oestrogen binding and serum lipids of postmenopausal women with breast cancer. Austr N Z J Surg. 1990; 60:673-675.
12. Williams JK, Wagner JD, Li Z, Golden DL, Adams MR. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arterioscler Thromb Vasc Biol. 1997;17:403-408.
13. Guetta V, Lush RM, Figg WD, Waclawiw MA, Cannon RO. Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. Am J Cardiol. 1995;76:1072-1073.
14. Heistad DD, Armstrong ML, Marcus ML, Piegors DJ, Mark AL. Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys. Circ Res. 1984;54:711-718.
15. Ludmer PL, Selwyn AP, Shook THL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046-1051.
16. Harrison DG, Freiman PC, Armstrong ML, Marcus ML, Heistad DD. Alterations of vascular reactivity in atherosclerosis. Circ Res. 1987;61(suppl II):II-74-II-80.
17. Zeiher AM, Drexler H, Wollschläger H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of atherosclerosis. Circulation. 1991;83:391-401.
18. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. The coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1989;81:491-497.
19. Reddy KG, Nair R, Sheehan HM, Hodgson JM. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol. 1994;23:833-843.
20. Herrington DM, Braden GA, Downes TR, Williams JK. Estrogen modulates coronary vasomotor responses in postmenopausal women with early atherosclerosis. Am J Cardiol. 1994;73:951-952.
21. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO III. Acute vascular effects of estrogen in postmenopausal women. Circulation. 1994;90:786-791.
22. Gilligan DM, Quyyumi AA, Cannon RO III. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 1994;89:2545-2551.
23. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation. 1994;89:52-60.
24. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation. 1990;81: 1680-1687.
25. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol. 1992;20: 452-457.
26. Williams JK, Honoré EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol. 1994;24: 1757-1761.
27. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary atherosclerosis: lack of an effect of added progesterone. Arteriosclerosis. 1990;10:1051-1057.
28. Adams MR, Clarkson TB, Koritnik DR, Nash HA. Contraceptive steroids and coronary artery atherosclerosis in cynomolgus monkeys. Fertil Steril. 1987;47:1010-1018.
29. Clarkson TB, Shively CA, Morgan TM, Koritnik DR, Adams MR, Kaplan JR. Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys. Obstet Gynecol. 1990;75:217-222.
30. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20: 470-475.
31. Lipid Research Clinics Program. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis (revised 1982). Bethesda, Md: National Institutes of Health; 1984. US Department of Health, Education, and Welfare publication NIH 75-628.
32. Fossati P, Principe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28:2077-2080.
33. Carroll RM, Rudel LL. Lipoprotein separations and low density lipoprotein molecular weight determination using high performance gel-filtration chromatography. J Lipid Res. 1983;24:200-207.
34. Auerbach BJ, Parks JS, Applebaum-Bowden D. A rapid and sensitive micro-assay for the enzymatic determination of plasma and lipoprotein cholesterol. J Lipid Res. 1990;31:738-742.
35. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst. 1991;83:1450-1459.
36. Jiang C, Sarrel PM, Poole-Wilson PA, Collins P. Acute effect of 17β-estradiol on rabbit coronary artery contractile responses to endothelin-1. Am J Physiol. 1992;263:H271-H275.
37. Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Endothelium-independent relaxation of rabbit coronary artery by 17β-oestradiol in vitro. Br J Pharmacol. 1991;104:1033-1037.
38. Fischer GM, Bashey RI, Rosenbaum H, Lyttle CR. A possible mechanism in arterial wall for mediation of sex difference in atherosclerosis. Exp Mol Pathol. 1985;43:288-296.
39. McGill HC, Sheridan PJ. Nuclear uptake of sex steroid hormones in the cardiovascular system of the baboon. Circ Res. 1981;48: 238-244.
40. Lin AL, McGill HC, Shain SA. Hormone receptors of the baboon cardiovascular system. Arteriosclerosis. 1981;1:257-264.
41. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation. 1994;89:1501-1510.
42. Prentice RL. Tamoxifen as a potential preventive agent in healthy postmenopausal women. J Natl Cancer Inst. 1990;82:1310-1311.
43. Hardell L. Tamoxifen as a risk factor for carcinoma of corpus uteri. Lancet. 1988;2:563.
44. Malfetano JH. Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol. 1990;39: 82-84.
45. Atlante G, Pozzi M, Vincenzoni C, Vocaturo G. Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol. 1989;37:378-380.
46. Rutqvist LE, Mattsson A, for the Stockholm Breast Cancer Study Group. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst. 1993;85:1398-1406.